CRYGA

Across TCGA pan-cancer cohorts, CRYGA RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated CRYGA data layer compared with 7 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CRYGA RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CRYGA expression acts as an unfavorable survival marker, although some lineages such as LGG and UCS show a favorable association.

LIHC, SKCM, and CESC are the cancer types where CRYGA RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	II,III,IV	0.055	0.785	<.001	102	view →
SKCM	DFS	Tertile	All	0.521	0.751	<.001	87	view →
CESC	OS	Tertile	IV	0.091	0.593	<.001	36	view →
LGG	OS	Median	All	0.878	0.744	<.001	34	view →
COAD	OS	Tertile	IV	0.140	0.657	.005	27	view →
ACC	OS	Tertile	All	0.118	0.624	.038	18	view →
SARC	DFS	Tertile	All	0.332	0.642	.021	18	view →
UCS	OS	Tertile	II,III,IV	1.000	0.346	.039	12	view →
STAD	DFS	Tertile	IV	0.083	0.379	.001	9	view →
PCPG	DFS	Tertile	All	0.535	0.935	.040	9	view →
THCA	DFS	Tertile	II,III,IV	0.774	0.927	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

CRYGA–LIHC (OS)

Open the LIHC breakdown →